Dupilumab inhibits the interleukin-4 receptor subunit α and is FDA approved for 
treatment of moderate-to-severe atopic dermatitis. It is a relatively new drug, 
and whether it is efficacious for other diseases in dermatology is an area of 
increasing interest. We searched the literature and ClinicalTrials.gov database 
for uses of dupilumab beyond atopic dermatitis in dermatology and for ongoing 
studies on new uses for dupilumab. Off-label reports identified described use of 
dupilumab for several different dermatologic conditions, including allergic 
contact dermatitis, hand dermatitis, chronic spontaneous urticaria, prurigo 
nodularis, and alopecia areata. Overall, there is limited but promising data for 
dupilumab use beyond atopic dermatitis in dermatology. The relatively safe 
adverse effect profile of dupilumab may make it an option for certain 
recalcitrant diseases in dermatology, but further studies will be needed to 
assess its efficacy and determine its best possible use. J Drugs Dermatol. 
2019;18(10):1053-1055.